Nu.Q® Discover Expands Global Adoption and Epigenetic Innovation

Core Insights - Nu.Q® Discover targets a total addressable market of $200 million annually, serving as a strong source of early revenue and validating the platform's utility with major healthcare companies [1] - The platform features a portfolio of 14 advanced immunoassays and is currently serving over 20 clients globally, facilitating disease research and drug development across various therapeutic areas [1] - Volition anticipates continued growth in 2025, with expectations of multiple new contracts based on established scientific excellence and commercial traction [1] Company Developments - Dr. Jasmine Kway, CEO of Singapore Volition, noted strong demand for Nu.Q® assays as exploratory biomarkers in multinational clinical trials, with significant projected revenue from ongoing studies [2] - The company is exploring co-marketing partnerships to meet the increasing global demand for Nu.Q® Discover, aiming to sign such deals in the near future [3] - The Nu.Q® Discover platform supports the entire drug development continuum, with applications in oncology, neurodegenerative diseases, autoimmune diseases, and NETosis [4] Market Position - The Nu.Q® platform's versatility has been validated in a peer-reviewed publication, enhancing its credibility in the life sciences community [1] - The ongoing service expansion and robust pipeline suggest strong revenue growth for Nu.Q® Discover this year [3] - If Nu.Q® assays advance to companion diagnostic use, this could lead to high-value, long-term partnerships worth millions [3]